The AMPA antagonists NBQX and GYKI 52466 do not counteract neuroleptic-induced catalepsy.
The AMPA antagonists NBQX (2.5, 5, 10 mg/kg) and GYKI 52466 (4.8, 8 mg/kg) were investigated in haloperidol (0.5 mg/kg)-induced catalepsy in the rat. The effects of AMPA antagonists administered either alone or in combination with the noncompetitive NMDA antagonist dizocilpine (0.02 mg/kg), with the dopamine D-2 agonist quinpirole (1 mg/kg) or with L-DOPA (50, 100 mg/kg plus benserazide) were tested. NBQX or GYKI 52466 did not exert anticataleptic effects, neither alone nor in combination with dizocilpine, quinpirole or L-DOPA. Thus, in the rat inhibition of AMPA receptors with NBQX or GYKI 52466 does not have effects predictive for an antiparkinsonian potential.
Zadow
B
B
Zoological Institute, University of Tübingen, Germany.
Schmidt
W J
WJ
D000818:Animals; D014151:Anti-Anxiety Agents; D014150:Antipsychotic Agents; D001569:Benzodiazepines / Q000494:pharmacology*; D002375:Catalepsy / Q000139:chemically induced* / Q000188:drug therapy*; D016291:Dizocilpine Maleate / Q000494:pharmacology; D004347:Drug Interactions; D004873:Ergolines / Q000494:pharmacology; D006220:Haloperidol; D007980:Levodopa / Q000494:pharmacology; D008297:Male; D010865:Pilot Projects; D011810:Quinoxalines / Q000494:pharmacology*; D019257:Quinpirole; D051381:Rats; D017207:Rats, Sprague-Dawley; D018091:Receptors, AMPA / Q000037:antagonists & inhibitors*
D014151:Anti-Anxiety Agents; D014150:Antipsychotic Agents; D004873:Ergolines; D011810:Quinoxalines; D018091:Receptors, AMPA; C061950:GYKI 52466; C062865:2,3-dioxo-6-nitro-7-sulfamoylbenzo(f)quinoxaline; D001569:Benzodiazepines; D019257:Quinpirole; D007980:Levodopa; D016291:Dizocilpine Maleate; D006220:Haloperidol